<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03280173</url>
  </required_header>
  <id_info>
    <org_study_id>B3461054</org_study_id>
    <secondary_id>2017-002769-23</secondary_id>
    <nct_id>NCT03280173</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood</brief_title>
  <official_title>A Phase 1, Open-label, Randomized, Four-period, Four-sequence, Single-dose, Crossover Study In Healthy Volunteers, To Determine The Relative Bioavailability Of Pf-06291826 61 Mga Tafamidis Free Acid Soft Gelatin Capsules Compared To Commercial 4 × 20 Mg Tafamidis Meglumine Soft Gelatin Capsules Administered Under Fasted And Fed Conditions And The Effect Of Food On The Oral Bioavailability Of Pf-06291826 61 Mga Tafamidis Free Acid Soft Gelatin Capsules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      2 different formulations of tafamidis will be compared under both fed and fasted conditions.
      Subjects will be fasted overnight or fed. After swallowing one of the tafamidis formulations,
      tafamidis blood concentrations will be measured periodically for 8 days. After 16 days,
      subjects will take a different formulation in the fed or fasted state or take the same
      formulation in the opposite feeding condition. This will be repeated, 16 days apart, until
      all subjects have taken each formulation both fed and fasted.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 29, 2017</start_date>
  <completion_date type="Actual">February 23, 2018</completion_date>
  <primary_completion_date type="Actual">February 23, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve 0-72 hours (AUC72)</measure>
    <time_frame>72 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum observed plasma concentration (Cmax)</measure>
    <time_frame>168 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>168 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>168 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>168 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>168 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from zero to infinity (AUCinf)</measure>
    <time_frame>168 hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>61 mgA tafamidis free acid soft gelatin capsule fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>61 mgA tafamidis free acid soft gelatin capsule fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 × 20 mg tafamidis meglumine soft gelatin capsules fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 × 20 mg tafamidis meglumine soft gelatin capsules fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fasted</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tafamidis</intervention_name>
    <description>bioavailability study</description>
    <arm_group_label>61 mgA tafamidis free acid soft gelatin capsule fed</arm_group_label>
    <arm_group_label>61 mgA tafamidis free acid soft gelatin capsule fasted</arm_group_label>
    <arm_group_label>4 × 20 mg tafamidis meglumine soft gelatin capsules fed</arm_group_label>
    <arm_group_label>4 × 20 mg tafamidis meglumine soft gelatin capsules fasted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females of non-child bearing potential.

          -  Body Mass Index (BMI) of 17.5 to 30.5 and total body weight more than 50 kg (110 lbs).

        Exclusion Criteria:

          -  Blood pressure at screening visit of greater than 140 mm Hg (systolic) or 90 mg Hg
             (diastolic).

          -  Use of prescription or nonprescription drugs supplements within 7 days prior to 7 days
             of the study.

          -  Pregnant female subjects; breastfeeding female subjects; male subjects with partners
             currently pregnant; male subjects able to father children who are unwilling or unable
             to use a highly effective method of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3461054&amp;StudyName=A+Phase+1%2C+Open-label%2C+Randomized%2C+Four-period%2C+Four-sequence%2C+Single-dose%2C+Crossover+Study+In+Healthy+Volunteers%2C+To+Determine+The+Relative+Bioavailability+Of+Pf-06291826+61+Mga+Tafamidis+Free+Acid+Soft+Gelatin+Capsules+Compared+To+Commercial+4+%C3%97+20+Mg+Tafamidis+Meglumine+Soft+Gelatin+Capsules+Administered+Under+Fasted+And+Fed+Conditions+And+The+Effect+Of+Food+On+The+Oral+Bioavailability+Of+Pf-06291826+61+Mga+Tafamidis+Free+Acid+Soft+Gelatin+Capsules</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2017</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

